ASX Announcements

Neuren receives final payment from Lanstead Capital
Results of Meeting
Chairman's Address at 2019 Annual Meeting of Shareholders
Validation for NNZ-2591 neurodevelopmental disorder pipeline
NNZ-2591 positive effects in Pitt Hopkins syndrome model
NNZ-2591 positive effects in Angelman syndrome model
Appendix 4C - quarterly
Notice of Annual General Meeting/Proxy Form
Appendix 4G
Annual Report to shareholders